{"title":"D-003与阿司匹林对实验性血栓模型的协同作用","authors":"V Molina, M.L Arruzazabala, D Carbajal, R Más","doi":"10.1016/S0952-3278(03)00020-6","DOIUrl":null,"url":null,"abstract":"<div><div><span><span>D-003 is a mixture of higher primary aliphatic saturated acids purified from sugarcane wax, with antiplatelet<span> and antithrombotic effects experimentally demonstrated. Octacosanoic acid is the main component of D-003, followed by triacontanoic, dotriacontanoic, and tetracontanoic acids, while other acids are minor components. This work investigates the effects of combination therapy D-003+aspirin (ASA) on arachidonic acid (AA)-induced </span></span>sudden death<span> in mice and bleeding time in rats. In addition, the effects of D-003 on serum levels of two metabolites of AA: thromboxane A</span></span><sub>2</sub><span> and prostacyclin, assessed through the measurement of their stable metabolites: thromboxane B</span><sub>2</sub> (TxB<sub>2</sub><span>) and 6 keto PgF1α by radioimmunoassay kits, were also investigated. Combination therapy of D-003 (50</span> <!-->mg/kg) and ASA (3<!--> <!-->mg/kg) significantly increased bleeding time in rats in a synergistic manner compared with D-003 or ASA alone. Moreover, the combined treatment of D-003 (200<!--> <!-->mg/kg) and ASA (5<!--> <span>mg/kg) in mice protected against AA-induced sudden death (83% survivors) in a synergistic manner which was compared with each treatment alone (33% survivors). These results indicate that antiplatelet effects of D-003 are not mediated by a cyclooxygenase<span> inhibition. D-003 and ASA monotherapies reduced serum TxB</span></span><sub>2</sub> levels, whereas D-003, but not ASA, significantly increased 6 keto PgF1α levels.</div></div>","PeriodicalId":94179,"journal":{"name":"Prostaglandins, leukotrienes, and essential fatty acids","volume":"68 5","pages":"Pages 305-310"},"PeriodicalIF":3.2000,"publicationDate":"2003-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synergistic effect of D-003 and aspirin on experimental thrombosis models\",\"authors\":\"V Molina, M.L Arruzazabala, D Carbajal, R Más\",\"doi\":\"10.1016/S0952-3278(03)00020-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><span><span>D-003 is a mixture of higher primary aliphatic saturated acids purified from sugarcane wax, with antiplatelet<span> and antithrombotic effects experimentally demonstrated. Octacosanoic acid is the main component of D-003, followed by triacontanoic, dotriacontanoic, and tetracontanoic acids, while other acids are minor components. This work investigates the effects of combination therapy D-003+aspirin (ASA) on arachidonic acid (AA)-induced </span></span>sudden death<span> in mice and bleeding time in rats. In addition, the effects of D-003 on serum levels of two metabolites of AA: thromboxane A</span></span><sub>2</sub><span> and prostacyclin, assessed through the measurement of their stable metabolites: thromboxane B</span><sub>2</sub> (TxB<sub>2</sub><span>) and 6 keto PgF1α by radioimmunoassay kits, were also investigated. Combination therapy of D-003 (50</span> <!-->mg/kg) and ASA (3<!--> <!-->mg/kg) significantly increased bleeding time in rats in a synergistic manner compared with D-003 or ASA alone. Moreover, the combined treatment of D-003 (200<!--> <!-->mg/kg) and ASA (5<!--> <span>mg/kg) in mice protected against AA-induced sudden death (83% survivors) in a synergistic manner which was compared with each treatment alone (33% survivors). These results indicate that antiplatelet effects of D-003 are not mediated by a cyclooxygenase<span> inhibition. D-003 and ASA monotherapies reduced serum TxB</span></span><sub>2</sub> levels, whereas D-003, but not ASA, significantly increased 6 keto PgF1α levels.</div></div>\",\"PeriodicalId\":94179,\"journal\":{\"name\":\"Prostaglandins, leukotrienes, and essential fatty acids\",\"volume\":\"68 5\",\"pages\":\"Pages 305-310\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2003-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostaglandins, leukotrienes, and essential fatty acids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0952327803000206\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2003/4/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins, leukotrienes, and essential fatty acids","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952327803000206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2003/4/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Synergistic effect of D-003 and aspirin on experimental thrombosis models
D-003 is a mixture of higher primary aliphatic saturated acids purified from sugarcane wax, with antiplatelet and antithrombotic effects experimentally demonstrated. Octacosanoic acid is the main component of D-003, followed by triacontanoic, dotriacontanoic, and tetracontanoic acids, while other acids are minor components. This work investigates the effects of combination therapy D-003+aspirin (ASA) on arachidonic acid (AA)-induced sudden death in mice and bleeding time in rats. In addition, the effects of D-003 on serum levels of two metabolites of AA: thromboxane A2 and prostacyclin, assessed through the measurement of their stable metabolites: thromboxane B2 (TxB2) and 6 keto PgF1α by radioimmunoassay kits, were also investigated. Combination therapy of D-003 (50 mg/kg) and ASA (3 mg/kg) significantly increased bleeding time in rats in a synergistic manner compared with D-003 or ASA alone. Moreover, the combined treatment of D-003 (200 mg/kg) and ASA (5 mg/kg) in mice protected against AA-induced sudden death (83% survivors) in a synergistic manner which was compared with each treatment alone (33% survivors). These results indicate that antiplatelet effects of D-003 are not mediated by a cyclooxygenase inhibition. D-003 and ASA monotherapies reduced serum TxB2 levels, whereas D-003, but not ASA, significantly increased 6 keto PgF1α levels.